emfilermin
Recombinant proteinexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2001 (NCT00504530)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Leukemia inhibitory factorSupplementation
LIF supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108400 ↗
Also known as
- emfilermin
- emfilermin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00504608 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2003 | Merck KGaA, University of Cambridge |
| NCT00504530 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2001 | Merck KGaA, University of Cambridge |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 2 | 2 | 1 | 2001 |
| University of Cambridge | Academic/Hospital | 2 | 0 | 1 | 2001 |
2 organizations
Page 1 / 1